CAR T-cell therapy has transformed the treatment landscape for relapsed/refractory multiple myeloma (RRMM) with therapies like cilta-cel and ide-cel showing significant improvements in patient outcomes. However, challenges such as lengthy manufacturing and wait times, especially for rapidly progressing patients, pose significant risks, with up to 10% not reaching CAR T infusion. Patients with high disease burden or rapidly relapsing disease who do receive CAR T often face worse outcomes and increased toxicity. Moreover, late-relapse patients who have exhausted conventional treatments may lack effective bridging options to manage the disease before CAR T-cell therapy.
Innovative bridging strategies are essential to control disease burden, stabilize patients, and optimize their readiness for CAR T-cell therapy, particularly for those with aggressive or heavily pretreated disease. Notably, bridging therapies should target antigens different from BCMA if BCMA-directed CAR T-cell therapy is planned to avoid compromising the efficacy of the subsequent BCMA-targeted therapy. Data suggest that using a BCMA-targeting agent before CAR T-cell therapy could negatively impact the outcome of the BCMA CAR T-cell therapy, emphasizing the importance of selecting bridging treatments that minimize disease burden without interfering with the main CAR T-cell therapy’s target antigen.
Studies are exploring sequential targeting in multiple myeloma and bridging therapy before CAR T-cell therapy to enhance patient outcomes. For instance, talquetamab is being investigated as a bridging therapy for late-relapse myeloma, showing promise in preparing patients for safer and more effective CAR T-cell therapy. While BCMA-directed CAR T-cell therapies have initially been approved for heavily pretreated patients, indications have expanded to include those with fewer prior lines of therapy, significantly improving the outlook for RRMM patients. However, addressing the challenges of manufacturing and wait times is crucial to ensure timely access to CAR T-cell therapy for all eligible patients.
The race against time in RRMM treatment underscores the urgent need for efficient bridging strategies to optimize patient outcomes. By targeting different antigens than BCMA in bridging therapies, the efficacy of subsequent BCMA CAR T-cell therapy can be preserved, maximizing treatment benefits for patients. Talquetamab and other innovative bridging therapies hold promise in enhancing the safety and effectiveness of CAR T-cell therapy for RRMM patients, offering hope for improved outcomes and quality of life. As the field continues to evolve, prioritizing research and development of bridging strategies will be critical in overcoming the challenges associated with CAR T-cell therapy and advancing personalized treatment approaches for RRMM.
- Innovative bridging strategies are essential to optimize the efficacy of CAR T-cell therapy for RRMM patients.
- Targeting different antigens in bridging therapies can preserve the efficacy of subsequent BCMA CAR T-cell therapy.
- Talquetamab and other emerging bridging therapies show promise in enhancing the safety and effectiveness of CAR T-cell therapy for late-relapse myeloma patients.
- Addressing manufacturing and wait time challenges is crucial to ensure timely access to CAR T-cell therapy for all eligible RRMM patients.
Read more on targetedonc.com